food and drug administration, Eli Lilly and compounding
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% ...
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Hims & Hers (HIMS) stock falls 8% as court denies injunction on FDA ruling for Eli Lilly's (LLY) Zepbound shortage. Read more ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
The move positions Lilly as a competitive alternative to compounded weight-loss drugs, especially as the FDA cracks down on off-brand versions. Eli Lilly announced in a press release last week ...
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.
Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback